Enduring undetectable MRD and updated outcomes in relapsed/refractory CLL after fixed-duration venetoclax-rituximab - Seymour, John F.; Kipps, Thomas J.; Eichhorst, Barbara F.; D'Rozario, James; Owen, Carolyn J.; Assouline, Sarit; Lamanna, Nicole; Robak, Tadeusz; de la Serna, Javier; Jaeger, Ulrich; Cartron, Guillaume; Montillo, Marco; et al. (Blood, 2022)
Keywords: Antineoplastic Combined Chemotherapy Protocols; Antineoplastic Combined Chemotherapy Protocols - adverse effects; Bendamustine Hydrochloride; Bendamustine Hydrochloride - adverse effects; Bridged Bicyclo Compounds, Heterocyclic; Bridged Bicyclo Compounds, Heterocyclic - adverse effects; Clinical Trials and Observations; Hematology; Human health and pathology; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Life Sciences; Neoplasm, Residual; Neoplasm, Residual - drug therapy; Neoplasm, Residual - etiology; Recurrence; Rituximab; Rituximab - adverse effects; Sulfonamides; Lymphoid Neoplasia; Clinical Trials and Observations; Free Research Articles